ClinicalTrials.gg
CompletedNCT07757061YQD-LAC-STCUpdated Aug 12, 2026

YQD Combined With Plant Lactobacillus for Slow Transit Constipation

An interventional study of YQD (Yìqì Jiànpí Decoction) and Plant-derived Lactobacillus in Constipation and Slow Transit Constipation, sponsored by First People's Hospital Of Lin'an District, Hangzhou. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by First People's Hospital Of Lin'an District, Hangzhou · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.

Enrollment
26th of 93
120 · median 100
Started
2025
with 14 others
No phase
56 of 109
21 open now
Registered
106th of 109
by date

Among the 109 studies in Constipation with a site in China, this one is the 26th largest by enrollment of the 93 interventional ones that give a count, is one of 15 that started in 2025, is one of 56 with no phase, and was the 106th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Constipation with a site in China, or all of them as a file.
02

Study summary

Slow transit constipation (STC) is a common and difficult-to-treat subtype of chronic constipation, characterized by reduced colonic motility and delayed stool passage. Current treatments often provide limited long-term relief, and many patients relapse after stopping medication. This study aims to evaluate whether combining a traditional Chinese herbal formula (Yìqì Jiànpí Decoction, YQD) with plant-derived Lactobacillus probiotics provides better and more sustained relief than either treatment alone or standard prokinetic therapy.

A total of 120 eligible patients with STC will be randomly assigned to four groups in a 1:1:1:1 ratio: (1) YQD + Lactobacillus + mosapride; (2) YQD + mosapride; (3) Lactobacillus + mosapride; (4) mosapride alone. The treatment lasts 8 weeks. The primary outcome is the change in Constipation Severity Score from baseline to week 8. Secondary outcomes include quality of life, colonic transit time, gut microbiota changes, and relapse rate during a 6-month follow-up period.

This study will provide evidence on whether an integrative TCM-probiotic strategy offers superior and more durable benefits for STC patients.

Read the detailed description

This is a single-center, prospective, assessor-blinded, parallel-group, superiority randomized controlled trial with a 1:1:1:1 allocation ratio. The study is conducted at the Department of Colorectal Surgery, The First People's Hospital of Lin'an District, Hangzhou, China.

Study Population: Adult patients (aged 18-75 years) diagnosed with slow transit constipation (STC) according to Rome IV criteria, with delayed colonic transit confirmed by a colon transit study (retention of ≥20% of markers at 72 hours). Key exclusion criteria include outlet obstruction constipation, secondary constipation due to organic diseases, history of abdominal surgery (except appendectomy or cholecystectomy), severe systemic illness, pregnancy or lactation, known allergy to any herbal ingredient or Lactobacillus preparation, and use of medications affecting gastrointestinal motility within 4 weeks before screening.

Interventions: All four groups receive a background therapy of mosapride citrate 5 mg three times daily for 8 weeks. On top of that: (1) Group A receives YQD (one dose daily) + plant-derived Lactobacillus (compound Lactobacillus tablets, 3 tablets twice daily); (2) Group B receives YQD + placebo for Lactobacillus; (3) Group C receives Lactobacillus + placebo for YQD; (4) Group D receives placebo for both YQD and Lactobacillus. The herbal decoction consists of 12 herbs: Cistanche deserticola (Roucongrong) 15 g, Atractylodes macrocephala (Baizhu) 15 g, Astragalus membranaceus (Huangqi) 20 g, Cynanchum wilfordii (Geshangiao) 15 g, Scrophularia ningpoensis (Xuanshen) 12 g, Raphanus sativus (Laifuzi) 15 g, Dioscorea opposita (Shanyao) 12 g, Galli Gigerii Endothelium Corneum (Jineijin) 15 g, Sesamum indicum (Heizhima) powder 12 g, Cyathula officinalis (Chuanniuxi) 15 g, Massa Medicata Fermentata (Shenqu) 15 g, and Colla Corii Asini (Ejiao) 12 g. One dose is decocted and concentrated to 100 mL, taken once daily in the morning.

Outcome Measures: The primary outcome is the change from baseline to week 8 in the Constipation Severity Score (CSS), which evaluates stool frequency, consistency, straining, abdominal pain, and use of aids. Secondary outcomes include: (1) change in Patient Assessment of Constipation Quality of Life (PAC-QOL) scores; (2) colonic transit measured by percentage of retained markers at 72 hours; (3) gut microbiota quantification via 16S rRNA PCR for Escherichia coli, Lactobacillus, and Bifidobacterium; (4) relapse rate during 6-month follow-up (assessed at 1, 3, and 6 months post-treatment); and (5) adverse events graded per CTCAE v5.0.

Sample Size: Based on pilot data, the mean CSS reduction in the triple-combination group is expected to be 6.0 (SD 3.5), versus 3.5 (SD 3.0) in the mosapride-alone group. To detect a difference of 2.5 points with 80% power and a two-sided alpha of 0.05, accounting for a 20% dropout rate, 30 patients per group (total 120) are required.

Statistical Analysis: Primary analysis will be on an intention-to-treat (ITT) basis; per-protocol analysis will be sensitivity. Baseline characteristics will be compared using ANOVA or chi-square tests. The primary outcome (change in CSS) will be analyzed by ANCOVA with baseline CSS as covariate and treatment group as fixed factor, followed by post-hoc pairwise comparisons with Bonferroni correction. Secondary continuous outcomes will be analyzed similarly. Relapse rates will be compared using chi-square tests. Repeated measures will use mixed-effects models. Missing data will be handled by multiple imputation. Two-sided p \< 0.05 will be considered statistically significant.

Ethics and Dissemination: The protocol has been approved by the Medical Ethics Committee of The First People's Hospital of Lin'an District, Hangzhou (approval number: LAYY-EC-2024-037). Written informed consent will be obtained from all participants. Results will be submitted for publication in a peer-reviewed journal and presented at national and international conferences.

03

Conditions studied

  • Constipation
  • Slow Transit Constipation

Browse trials for

Keywords

  • Slow Transit Constipation
  • Yìqì Jiànpí Decoction
  • Traditional Chinese Medicine
  • Lactobacillus
  • Probiotics
  • Gut Microbiota
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meeting the Rome IV criteria for functional constipation, with predominant slow transit type confirmed by a colon transit study (retention of ≥20% of markers at 72 hours).
  2. Age between 18 and 75 years.
  3. Ability to comply with study procedures and provide written .
  4. No use of antibiotics, probiotics, or other laxatives (except rescue) within 2 weeks before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Outlet obstruction constipation (confirmed by anorectal manometry or defecography).
  2. Secondary constipation due to organic diseases (e.g., colorectal cancer, inflammatory bowel disease).
  3. History of abdominal surgery (except appendectomy or cholecystectomy).
  4. Severe systemic illness (e.g., heart failure, renal failure, liver cirrhosis).
  5. Pregnancy or lactation.
  6. Known allergy to any herbal ingredient or Lactobacillus preparation.
  7. Use of medications affecting gastrointestinal motility (e.g., opioids, anticholinergics) within 4 weeks before screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    YQD + Lactobacillus + Mosapride

    Participants receive Yìqì Jiànpí Decoction (YQD) once daily, plant-derived Lactobacillus tablets (3 tablets twice daily), and mosapride citrate 5 mg three times daily for 8 weeks.

    Dietary Supplement: YQD (Yìqì Jiànpí Decoction) · Dietary Supplement: Plant-derived Lactobacillus · Drug: Mosapride Citrate

  • Active comparator
    YQD + Mosapride

    Participants receive Yìqì Jiànpí Decoction (YQD) once daily and mosapride citrate 5 mg three times daily for 8 weeks. (No probiotics)

    Dietary Supplement: YQD (Yìqì Jiànpí Decoction) · Drug: Mosapride Citrate

  • Active comparator
    Lactobacillus + Mosapride

    Participants receive plant-derived Lactobacillus tablets (3 tablets twice daily) and mosapride citrate 5 mg three times daily for 8 weeks. (No herbal decoction)

    Dietary Supplement: Plant-derived Lactobacillus · Drug: Mosapride Citrate

  • Active comparator
    Mosapride Alone

    Participants receive mosapride citrate 5 mg three times daily for 8 weeks as active comparator. (No herbal decoction, no probiotics)

    Drug: Mosapride Citrate

Interventions

  • Dietary supplementYQD (Yìqì Jiànpí Decoction)

    A 12-herb traditional Chinese medicine formula consisting of Cistanche deserticola (Roucongrong) 15 g, Atractylodes macrocephala (Baizhu) 15 g, Astragalus membranaceus (Huangqi) 20 g, Cynanchum wilfordii (Geshangiao) 15 g, Scrophularia ningpoensis (Xuanshen) 12 g, Raphanus sativus (Laifuzi) 15 g, Dioscorea opposita (Shanyao) 12 g, Galli Gigerii Endothelium Corneum (Jineijin) 15 g, Sesamum indicum (Heizhima) powder 12 g, Cyathula officinalis (Chuanniuxi) 15 g, Massa Medicata Fermentata (Shenqu) 15 g, and Colla Corii Asini (Ejiao) 12 g. One dose is immersed in 1000 mL distilled water for 30 min, boiled, then simmered for 30 min, filtered; the residue is re-boiled with another 1000 mL, combined, and concentrated to 100 mL. Patients take the entire 100 mL once daily in the morning for 8 weeks.

  • Dietary supplementPlant-derived Lactobacillus

    Commercially available compound Lactobacillus tablets containing ≥10⁹ CFU of plant-derived Lactobacillus strains per tablet. Patients take 3 tablets twice daily (morning and evening) for 8 weeks.

  • Mosapride citrate 5 mg tablets taken orally three times daily before meals for 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Constipation Severity Score (CSS)

    The Constipation Severity Score (CSS) is a validated instrument that evaluates five dimensions of constipation: stool frequency, stool consistency, straining, abdominal pain, and use of aids to defecation. The total score ranges from 0 (minimum) to 39 (maximum), with higher scores indicating greater constipation severity. The outcome is measured as the change from baseline to week 8 (Week 8 score minus Baseline score).

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Patient Assessment of Constipation Quality of Life (PAC-QOL) Score

    PAC-QOL is a 28-item questionnaire assessing constipation-related quality of life across four subdomains: physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction. Total scores range from 0 to 4, with higher scores indicating worse quality of life.

    Time frame: Baseline to Week 8

  2. Change in Colonic Transit Time - Percentage of Retained Markers at 72 Hours

    Colonic transit is assessed using a radiopaque marker method. Participants ingest a capsule containing 20 markers on Day 1, and a plain abdominal X-ray is taken at 72 hours. The percentage of retained markers is calculated. A retention rate of ≥20% at 72 hours confirms slow transit constipation.

    Time frame: Baseline to Week 8

  3. Change in Gut Microbiota Quantification

    Fecal samples are collected at baseline and week 8. DNA is extracted and 16S rRNA PCR quantification is performed for Escherichia coli, Lactobacillus, and Bifidobacterium. Results are expressed as CFU/g of wet stool.

    Time frame: Baseline to Week 8

  4. Relapse Rate During 6-Month Follow-Up

    Relapse is defined as recurrence of constipation symptoms meeting Rome IV criteria or CSS returning to ≥50% of baseline score. Follow-up assessments are conducted at 1, 3, and 6 months post-treatment.

    Time frame: Month 1, Month 3, and Month 6 post-treatment

  5. Incidence of Treatment-Related Adverse Events

    Adverse events are graded according to CTCAE v5.0 and recorded throughout the 8-week intervention period and 6-month follow-up. Safety is assessed by the number and severity of reported adverse events.

    Time frame: Week 0 through Month 6 post-treatment

07

Study locations

1 site
  • Department of Colorectal Surgery, The First People's Hospital of Lin'an District, Hangzhou
    Hangzhou, Zhejiang 311300, China
08

References and documents

Publications

  • Jiang D, Zhang J, Xia Z. Structural Advances in Voltage-Gated Sodium Channels. Front Pharmacol. 2022 Jun 3;13:908867. doi: 10.3389/fphar.2022.908867. eCollection 2022. PubMed 35721169 ↗
  • Narayanan V, Motlekar S, Kadhe G, Bhagat S. Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. Dermatol Ther (Heidelb). 2014 Dec;4(2):233-48. doi: 10.1007/s13555-014-0062-1. Epub 2014 Sep 12. PubMed 25212256 ↗
  • Dou X, Yang W, Ding Q, Han Q, Qian Q, Du Z, Fan Y, Wang C, Li S. Comprehensive Analysis of the Expression Profiles of Hepatic lncRNAs in the Mouse Model of Alcoholic Liver Disease. Front Pharmacol. 2021 Jul 29;12:709287. doi: 10.3389/fphar.2021.709287. eCollection 2021. PubMed 34393788 ↗
  • Foja S, Heinzelmann J, Viestenz A, Rueger C, Hecht S, Viestenz A. Evaluation of the Possible Influence of Povidone Iodine (PVI) Solution and Polyhexanide (PHMB) on Wound Healing in Corneal Epithelial Regeneration. J Clin Med. 2024 Jan 19;13(2):588. doi: 10.3390/jcm13020588. PubMed 38276094 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. The results of this study will be disseminated through publication in a peer-reviewed journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 17 months.

Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 17 months is close to that.

Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 11, 2026
StartActual
Jan 1, 2025
Primary completionActual
Jun 10, 2026
CompletionActual
Aug 1, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07757061
Lead sponsor
First People's Hospital Of Lin'an District, Hangzhou
Responsible party
Yongjian Liao (Chief Physician, Department of Colorectal Surgery, First People's Hospital Of Lin'an District, Hangzhou) — Principal investigator
First posted
Aug 11, 2026
Start date
Jan 1, 2025
Primary completion
Jun 10, 2026
Completion
Aug 1, 2026
Last update
Aug 12, 2026

Study contacts

Yongjian Liao, MD
principal investigator · First People's Hospital of Hangzhou

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion